Holen Sie sich die Stockscreener-App
0.5402
11.52%
-0.0703
Schlusskurs vom Vortag:
$0.6105
Offen:
$0.61
24-Stunden-Volumen:
148.16K
Relative Volume:
0.94
Marktkapitalisierung:
$13.39M
Einnahmen:
$368.00K
Nettoeinkommen (Verlust:
$-9.54M
KGV:
-1.1282
EPS:
-0.4788
Netto-Cashflow:
$-9.47M
1W Leistung:
-15.71%
1M Leistung:
-3.55%
6M Leistung:
-21.15%
1J Leistung:
-45.98%
1-Tages-Spanne:
$0.5402
$0.64
1-Wochen-Bereich:
$0.5402
$0.65
52-Wochen-Spanne:
$0.46
$1.55
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Firmenname
Lexaria Bioscience Corp
Sektor
Branche
Telefon
250-765-6424
Adresse
100 - 740 MCCURDY ROAD, KELOWNA
Compare LEXX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
0.5402 | 13.39M | 368.00K | -9.54M | -9.47M | -0.4788 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lexaria Bioscience Corp Aktie (LEXX) Neueste Nachrichten
Lexaria Bioscience Corp (LEXXW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lexaria Bioscience Corp (LEXXW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lexaria Bioscience Corp (LEXXW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lexaria Bioscience Corp (LEXX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lexaria Bioscience Corp (LEXX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lexaria Bioscience Corp (LEXXW) Institutional Confidence - TradingKey
Lexaria Bioscience Corp (LEXX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lexaria Bioscience Corp (LEXXW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lexaria Bioscience Corp (LEXX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lexaria Bioscience Corp (LEXX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lexaria Bioscience Corp (LEXX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lexaria Bioscience Corp (LEXX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lexaria Bioscience (LEXX) Advances Drug Delivery Technology - GuruFocus
GLP-1 "Arms Race" Intensifies as the Addressable Markets Continue to Expand - Investing News Network
GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand - Investing News Network
Lexaria says GLP-1 drugs are moving into more diseases and markets - Stock Titan
Lexaria Bioscience Corp (LEXXW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lexaria Bioscience Corp (LEXXW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
LEXX: Animal & Human GLP-1 Studies Continue - Yahoo Finance
Lexaria Bioscience (LEXX) Completes Dosing in Key Animal Study - GuruFocus
Lexaria completes dosing study on next-generation GLP-1 drugs By Investing.com - Investing.com Nigeria
Lexaria completes dosing study on next-generation GLP-1 drugs - Investing.com
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway - News-Press NOW
Weight-loss injection retatrutide tested as pill in Lexaria animal trial - Stock Titan
Whoosh Wellness Launches Physician-Guided Telehealth Platform Offering Oral-First Wellness Protocols and Prescribed Microdosing Programs - GlobeNewswire Inc.
Lexaria Bioscience to Attend BIO International Convention as Part of Expanded Business Development Push - citybuzz -
Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program - Investing News Network
Lexaria Attending the BIO International Convention, as part of a Broader Business Development Program - TradingView
Lexaria drug platform sees record partner interest ahead of BIO - Stock Titan
Lexaria Bioscience Corp.Common Stock (NQ: LEXX - FinancialContent
Lexaria Bioscience Finds its Niche in the Lucrative GLP-1 Market - The Globe and Mail
Lexaria Bioscience files to sell 2.76M shares of common stock for holders - MSN
Lexaria Gets Attention with GLP-1 Test on Deck - Bez Kabli
LEXX Should I Buy - Intellectia AI
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7 - Investing News Network
MarketsMedicine Hat News - FinancialContent
TradingKey - TradingKey
lxrp_ex991.htm - SEC.gov
Lexaria Bioscience Releases Second Episode of Investor Video Series - Investing News Network
What Lexaria's CEO says is next for GLP-1 research in 2026 - Stock Titan
Lexaria advances semaglutide study with ethics review submission By Investing.com - Investing.com India
Lexaria Updates Progress on Human Study #7 - Investing News Network
Lexaria advances semaglutide study with ethics review submission - Investing.com
Lexaria targets mid-June start for 5-week oral semaglutide study - Stock Titan
Lexaria Bioscience stock soars after ending $5M stock sale agreement with JonesTrading - MSN
Finanzdaten der Lexaria Bioscience Corp-Aktie (LEXX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):